Check Abstract A103 on the #EBMT20Virtual e-poster area
Background : Even if Chimeric Antigen Receptor (CAR)-T cells therapies are a promising way to treat relapsed/refractory hematologic cancers, authorities face major issues regarding their economic impact, the evaluation of their efficiency and adverse effects. Since their launch the number of patients with CAR-T cells indication is increasing, as well as the number of hematological cancers likely to be treated. Nationwide collections of biological resources are warranted to develop scientific projects to monitor CAR-T cells treatments and improve our understanding of the underlying biological mechanisms.
In this context, a biobanking initiative resulted from the collaboration of two French consortia : CALYM, gathering together the LYSA (Lymphoma Study Association), LYSARC (Lymphoma Academic Research Organization) and 18 academic laboratories in the field of lymphoma, and CRYOSTEM, a collaborative biobanking network. After demonstrating respectively their ability to set up the first collection of viable cells from lymphoma patients (CeVi_collection) and the first European collection of biological resources dedicated to Hematopoietic Stem Cell Transplantation, CRYOSTEM and CALYM joined their expertise to constitute a biocollection from lymphoma patients receiving CAR-T cells.

Visit the EBMT website for more information